|
1
|
Döhner H, Weisdorf DJ and Bloomfield CD:
Acute myeloid leukemia. N Engl J Med. 373:1136–1152. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Short NJ, Rytting ME and Cortes JE: Acute
myeloid leukaemia. Lancet. 392:593–606. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thol F, Schlenk RF, Heuser M and Ganser A:
How I treat refractory and early relapsed acute myeloid leukemia.
Blood. 126:319–327. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kurosawa S, Yamaguchi T, Miyawaki S,
Uchida N, Sakura T, Kanamori H, Usuki K, Yamashita T, Okoshi Y,
Shibayama H, et al: Prognostic factors and outcomes of adult
patients with acute myeloid leukemia after first relapse.
Haematologica. 95:1857–1864. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ramos NR, Mo CC, Karp JE and Hourigan CS:
Current approaches in the treatment of relapsed and refractory
acute myeloid leukemia. J Clin Med. 4:665–695. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bose P, Vachhani P and Cortes JE:
Treatment of relapsed/refractory acute myeloid leukemia. Curr Treat
Options Oncol. 18:172017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yanada M, Mori J, Aoki J, Masuko M, Harada
K, Uchida N, Doki N, Fukuda T, Sakura T, Kanamori H, et al:
Allogeneic hematopoietic cell transplantation for patients with a
history of multiple relapses of acute myeloid leukemia. Ann
Hematol. 98:2179–2186. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Robak T and Wierzbowska A: Cladribine in
the treatment of acute myeloid leukemia. Leuk Res. 38:425–427.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fridle C, Medinger M, Wilk MC, Seipel K,
Passweg J, Manz MG and Pabst T: Cladribine, cytarabine and
idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid
leukemia (AML). Leuk Lymphoma. 58:1068–1075. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Xiao H, Li L, Pang Y, Wu Y, Jiang Z, Liu
Z, Wu J, Xiao Y, Huang F, Liu Q, et al: Sequential treatment
combining cladribine-based re-induction, myeloablative allogeneic
HSCT, and prophylactic donor lymphocyte infusion: A promising
treatment for refractory acute myeloid leukemia. Ann Hematol.
97:2479–2490. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jin M, Hu Y, Wu W, Luo Y, Tan Y, Yu J, Jin
A, Yang L, Huang H and Wei G: Decitabine plus CLAG chemotherapy as
a bridge to haploidentical transplantation in the setting of acute
myeloid leukemia relapse after HLA-matched sibling transplantation:
A case report. BMC Cancer. 19:2422019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamamoto K, Kawamoto S, Kakiuchi S,
Yakushijin K, Matsuoka H and Minami H: Translocation t (11;19)
(q23; q13.1) without MLL rearrangement in acute myeloid leukemia:
Heterogeneity of the 11q23 Breakpoints. Acta Haematol. 134:76–79.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bhatnagar B, Blachly JS, Kohlschmidt J,
Eisfeld AK, Volinia S, Nicolet D, Carroll AJ, Block AW, Kolitz JE,
Stone RM, et al: Clinical features and gene- and
microRNA-expression patterns in adult acute leukemia patients with
t (11;19) (q23; p13.1) and t (11;19) (q23; p13.3). Leukemia.
30:1586–1589. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen Y, Kantarjian H, Pierce S, Faderl S,
O'Brien S, Qiao W, Abruzzo L, de Lima M, Kebriaei P, Jabbour E, et
al: Prognostic significance of 11q23 aberrations in adult acute
myeloid leukemia and the role of allogeneic stem cell
transplantation. Leukemia. 27:836–842. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wierzbowska A, Robak T, Pluta A,
Wawrzyniak E, Cebula B, Hołowiecki J, Kyrcz-Krzemień S, Grosicki S,
Giebel S, Skotnicki AB, et al: Cladribine combined with high doses
of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a
highly effective salvage regimen in patients with refractory and
relapsed acute myeloid leukemia of the poor risk: A final report of
the Polish Adult Leukemia Group. Eur J Haematol. 80:115–126. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Halpern AB, Othus M, Huebner EM, Buckley
SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS,
Hendrie PC, Chen TL, et al: Mitoxantrone, etoposide and cytarabine
following epigenetic priming with decitabine in adults with
relapsed/refractory acute myeloid leukemia or other high-grade
myeloid neoplasms: A phase 1/2 study. Leukemia. 31:2560–2567. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
World Medical Association, . World Medical
Association Declaration of Helsinki: Ethical principles for medical
research involving human subjects. JAMA. 310:2191–2194. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pallisgaard N, Hokland P, Riishøj DC,
Pedersen B and Jørgensen P: Multiplex reverse
transcription-polymerase chain reaction for simultaneous screening
of 29 translocations and chromosomal aberrations in acute leukemia.
Blood. 92:574–588. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang YL, Lin SR, Chen JS, Hsiao CC, Lin
KH, Sheen JM, Cheng CN, Wu KH, Lin SW, Yu SL, et al: Multiplex
reverse transcription-polymerase chain reaction as diagnostic
molecular screening of 4 common fusion chimeric genes in Taiwanese
children with acute lymphoblastic leukemia. J Pediatr Hematol
Oncol. 32:e323–e330. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gou H, Zhou J, Ye Y, Hu X, Shang M, Zhang
J, Zhao Z, Peng W, Zhou Y, Zhou Y, et al: The prevalence and
clinical profles of FLT3-ITD, FLT3-TKD, NPM1, C-KIT, DNMT3A, and
CEBPA mutations in a cohort of patients with de novo acute myeloid
leukemia from southwest China. Tumour Biol. 37:7357–7370. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bennett JM, Catovsky D, Daniel MT,
Flandrin G, Galton DA, Gralnick HR and Sultan C: Proposals for the
classification of the acute leukaemias. French-American-British
(FAB) co-operative group. Br J Haematol. 33:451–458. 1976.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Creutzig U, van den Heuvel-Eibrink MM,
Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H,
Johnston D, Kinoshita A, et al: Diagnosis and management of acute
myeloid leukemia in children and adolescents: Recommendations from
an international expert panel. Blood. 120:3187–3205. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Van Limbergen H, Poppe B, Michaux L,
Herens C, Brown J, Noens L, Berneman Z, De Bock R, De Paepe A and
Speleman F: Identification of cytogenetic subclasses and recurring
chromosomal aberrations in AML and MDS with complex karyotypes
using M-FISH. Genes Chromosomes Cancer. 33:60–72. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meyer C, Hofmann J, Burmeister T, Gröger
D, Park TS, Emerenciano M, Pombo de Oliveira M, Renneville A,
Villarese P, Macintyre E, et al: The MLL recombinome of acute
leukemias in 2013. Leukemia. 27:2165–2176. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reimer J, Knöß S, Labuhn M, Charpentier
EM, Göhring G, Schlegelberger B, Klusmann JH and Heckl D:
CRISPR-Cas9-induced t (11;19)/MLL-ENL translocations initiate
leukemia in human hematopoietic progenitor cells in vivo.
Haematologica. 102:1558–1566. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Steckel NK, Groth C, Mikesch JH, Trenschel
R, Ottinger H, Kordelas L, Mueller-Tidow C, Schliemann C, Reicherts
C, Albring JC, et al: High-dose melphalan-based sequential
conditioning chemotherapy followed by allogeneic haematopoietic
stem cell transplantation in adult patients with relapsed or
refractory acute myeloid leukaemia. Br J Haematol. 180:840–853.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cui L, Liu Y, Pang Y, Qian T, Quan L,
Cheng Z, Dai Y, Ye X, Pang Y, Shi J, et al: Emerging agents and
regimens for treatment of relapsed and refractory acute myeloid
leukemia. Cancer Gene Ther. 27:1–14. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Westhus J, Noppeney R, Dührsen U and
Hanoun M: FLAG salvage therapy combined with idarubicin in
relapsed/refractory acute myeloid leukemia. Leuk Lymphoma.
60:1014–1022. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang L, Xu J, Tian X, Lv T and Yuan G:
Analysis of efficacy and prognostic factors of CLAG treatment in
Chinese patients with refractory or relapsed acute myeloid
leukemia. Acta Haematol. 141:43–53. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bao Y, Zhao J and Li ZZ: Comparison of
clinical remission and survival between CLAG and FLAG induction
chemotherapy in patients with refractory or relapsed acute myeloid
leukemia: A prospective cohort study. Clin Transl Oncol.
20:870–880. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Amadori S, Arcese W, Isacchi G, Meloni G,
Petti MC, Monarca B, Testi AM and Mandelli F: Mitoxantrone,
etoposide, and intermediate-dose cytarabine: An effective and
tolerable regimen for the treatment of refractory acute myeloid
leukemia. J Clin Oncol. 9:1210–1214. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ringden O, Labopin M, Ehninger G,
Niederwieser D, Olsson R, Basara N, Finke J, Schwerdtfeger R, Eder
M, Bunjes D, et al: Reduced intensity conditioning compared with
myeloablative conditioning using unrelated donor transplants in
patients with acute myeloid leukemia. J Clin Oncol. 27:4570–4577.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Luger SM, Ringden O, Zhang MJ, Perez WS,
Bishop MR, Bornhauser M, Bredeson CN, Cairo MS, Copelan EA, Gale
RP, et al: Similar outcomes using myeloablative vs.
reduced-intensity allogeneic transplant preparative regimens for
AML or MDS. Bone Marrow Transplant. 47:203–211. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang L, Devillier R, Wan M, Decroocq J,
Tian L, Fürst S, Wang LN, Vey N, Fan X, Blaise D and Hu J: Clinical
outcome of FLAG-IDA chemotherapy sequential with Flu-Bu3
conditioning regimen in patients with refractory AML: A parallel
study from Shanghai Institute of Hematology and Institut
Paoli-Calmettes. Bone Marrow Transplant. 54:458–464. 2019.
View Article : Google Scholar : PubMed/NCBI
|
